Aytu BioScience (AYTU) has hired Matthew Phillips as Executive Vice President of Commercial Operations, effective November 8, 2019. He will report to Josh
Nano cap Aytu BioScience (NASDAQ:AYTU) is up 3% premarket on modest volume following its announcement that Natesto (testosterone) prescriptions in fiscal Q2 (calendar Q4 2018) were...
CDTi Advanced Materials (NASDAQ:CDTI) -61% on Q3 earnings. Pyxis Tankers (NASDAQ:PXS) -31% on Q3 earnings. RYB Education (NYSE:RYB) -26%. IZEA Worldwide (NASDAQ:IZEA) -21% on Q3...
Investors’ focus will be on the sales performance of Natesto and the newly added products ZolpiMist and Tuzistra XR when Aytu BioScience, Inc. (NASDAQ:AYTU) reports...
For Immediate ReleaseChicago, IL –July 8, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have displayed a solid uptrend so far this year. The biotech company’s stock has rallied 38.1% compared with 3.8%...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Dark Cloud Cover||1D||1||Nov 14, 2019|
|Bullish Engulfing||1D||2||Nov 13, 2019|
|Dragonfly Bearish||1H||3||Nov 14, 2019 02:00PM|
|Tri-Star Bearish||30||3||Nov 14, 2019 03:00PM|
|Three Outside Up||5H||4||Nov 13, 2019 01:00PM|
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.